India exports Covid-19 vaccines worth about Rs 338 cr so far: Goyal

The exports include grant of the vaccine doses to friendly countries and commercial shipments

coronavirus vaccine, vaccine, Covid-19 vaccine
India is taking care of the domestic vaccine requirement first and based on that "giving vaccines to friendly countries," he said.
Press Trust of India New Delhi
2 min read Last Updated : Feb 12 2021 | 1:10 PM IST

India's exports of the COVID-19 vaccine stood at around Rs 338 crore till February 8, Commerce and Industry Minister Piyush Goyal said in the Rajya Sabha on Friday.

The exports include grant of the vaccine doses to friendly countries and commercial shipments.

Replying to supplementary questions in the House, Goyal said exports of the vaccine started in January.

India is taking care of the domestic vaccine requirement first and based on that "giving vaccines to friendly countries," he said.

"Total export is about Rs 338 crore worth of COVID vaccine," the minister said.

Giving details, Goyal said export of Covishield vaccine manufactured by the Serum Insitute of India, Pune as Government of India grant stood at 62.7 lakh doses with FoB (free on board) value of about Rs 125.4 crore.

Paid exports of 1.05 crore doses were valued at about Rs 213.32 crore.

Goyal said the government has granted permission to the Serum Institute and Bharat Biotech International Limited, Hyderabad for manufacture of COVID-19 vaccines.

Close coordination is being maintained through regular interaction between relevant departments of the Government of India and vaccine manufacturers to ensure adequate availability of COVID-19 vaccines for the national vaccination program, he added.

The minister further said the health ministry is working along with all states, and the Prime Minister is also interacting with all states.

Highest priority for vaccination has been given to healthcare and frontline workers by the government, Goyal said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusPiyush GoyalCoronavirus Vaccine

First Published: Feb 12 2021 | 1:01 PM IST

Next Story